Science
Overview
Microbion’s novel technology is centered around developing a new class of antimicrobial compounds for the treatment of serious resistant and difficult to treat infections. Microbion’s compounds have demonstrated antibacterial efficacy against a broad range of Gram-negative and Gram-positive bacteria, and their associated biofilms. Microbial biofilms have been associated with a wide variety of persistent infections which respond very poorly to conventional antibiotic therapy. This dual antimicrobial action represents first-in-class and best-in-class potential, providing an innovative clinical approach to treating a wide variety of challenging, serious infections.